283 related articles for article (PubMed ID: 35983569)
1. Current and emerging biologic therapies targeting eosinophilic disorders.
Pitlick MM; Li JT; Pongdee T
World Allergy Organ J; 2022 Aug; 15(8):100676. PubMed ID: 35983569
[TBL] [Abstract][Full Text] [Related]
2. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
3. Eosinophilic respiratory disorders and the impact of biologics.
Bernstein JS; Wechsler ME
Curr Opin Pulm Med; 2023 May; 29(3):202-208. PubMed ID: 36866734
[TBL] [Abstract][Full Text] [Related]
4. Targeting eosinophils: severe asthma and beyond.
Caminati M; Menzella F; Guidolin L; Senna G
Drugs Context; 2019; 8():212587. PubMed ID: 31391853
[TBL] [Abstract][Full Text] [Related]
5. Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes.
Olaguibel JM; Sastre J; Rodríguez JM; Del Pozo V
J Investig Allergol Clin Immunol; 2022 Jun; 32(3):165-180. PubMed ID: 35522053
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.
Roufosse F
Front Med (Lausanne); 2018; 5():49. PubMed ID: 29682504
[TBL] [Abstract][Full Text] [Related]
7. Eosinophil-associated diseases: the allergist's and clinical immunologist's perspective.
Marra AM; Rossi CM; Piga MA; Moroncini G; Bilò MB
Eur Ann Allergy Clin Immunol; 2024 Mar; ():. PubMed ID: 38546414
[TBL] [Abstract][Full Text] [Related]
8. Coexistence of Eosinophilic Granulomatosis With Polyangiitis and Allergic Bronchopulmonary Aspergillosis: A Fascinating Relationship.
Marra AM; Curci P; Franco G; Pittalis G; Tugnoli E; Cavasin D; Cristiano A; Bini F
Cureus; 2024 Apr; 16(4):e57917. PubMed ID: 38601813
[TBL] [Abstract][Full Text] [Related]
9. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Harish A; Schwartz SA
Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
[TBL] [Abstract][Full Text] [Related]
10. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
Nagase H; Ueki S; Fujieda S
Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
[TBL] [Abstract][Full Text] [Related]
11. Benralizumab in the management of rare primary eosinophilic lung diseases.
Griscti Soler D; Bennici A; Brunetto S; Gangemi S; Ricciardi L
Allergy Asthma Proc; 2022 Nov; 43(6):494-500. PubMed ID: 36335418
[No Abstract] [Full Text] [Related]
12. Biologics in eosinophilic gastrointestinal diseases.
Dellon ES; Spergel JM
Ann Allergy Asthma Immunol; 2023 Jan; 130(1):21-27. PubMed ID: 35738437
[TBL] [Abstract][Full Text] [Related]
13. Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis.
Matsuno O; Minamoto S
Respir Med Case Rep; 2022; 40():101763. PubMed ID: 36353062
[TBL] [Abstract][Full Text] [Related]
14. From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
Pavord ID; Bel EH; Bourdin A; Chan R; Han JK; Keene ON; Liu MC; Martin N; Papi A; Roufosse F; Steinfeld J; Wechsler ME; Yancey SW
Allergy; 2022 Mar; 77(3):778-797. PubMed ID: 34402066
[TBL] [Abstract][Full Text] [Related]
15. Targeted Molecular Therapies in Allergy and Rhinology.
Damask CC; Ryan MW; Casale TB; Castro M; Franzese CB; Lee SE; Levy JM; Lin SY; Lio PA; Peters AT; Platt MP; White AA
Otolaryngol Head Neck Surg; 2021 Jan; 164(1_suppl):S1-S21. PubMed ID: 33138725
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab.
Ricciardi L; Soler DG; Bennici A; Brunetto S; Pioggia G; Gangemi S
Front Pharmacol; 2022; 13():858344. PubMed ID: 35462932
[No Abstract] [Full Text] [Related]
17. The spectrum of therapeutic activity of mepolizumab.
Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
[No Abstract] [Full Text] [Related]
18. Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases.
Del Pozo V; Bobolea I; Rial MJ; Espigol-Frigolé G; Solans Laqué R; Hernández-Rivas JM; Mora E; Crespo-Lessmann A; Izquierdo Alonso JL; Domínguez Sosa MS; Maza-Solano J; Atienza-Mateo B; Bañas-Conejero D; Moure AL; Rúa-Figueroa Í
Front Immunol; 2023; 14():1310211. PubMed ID: 38250075
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab.
Menzella F; Galeone C; Ghidoni G; Ruggiero P; Capobelli S; Simonazzi A; Catellani C; Scelfo C; Livrieri F; Facciolongo N
Multidiscip Respir Med; 2021 Jan; 16(1):779. PubMed ID: 34221399
[TBL] [Abstract][Full Text] [Related]
20. A pragmatic guide to choosing biologic therapies in severe asthma.
Kavanagh JE; Hearn AP; Jackson DJ
Breathe (Sheff); 2021 Dec; 17(4):210144. PubMed ID: 35296105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
